Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
about
Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysisPhase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastomaPhase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory NeuroblastomaImpact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapyResponse, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".PPARgamma in Neuroblastoma.Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastomaIodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors.Radionuclide therapy of adrenal tumors.The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.Cotransfecting norepinephrine transporter and vesicular monoamine transporter 2 genes for increased retention of metaiodobenzylguanidine labeled with iodine 131 in malignant hepatocarcinoma cells.Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with (131)I-metaiodobenzylguanidine with implications for the activity to administer.Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.Norepinephrine Transporter as a Target for Imaging and Therapy.Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: reports so far and future perspective.The potential role of pretransplant MIBG diagnostic scintigraphy in targeted administration of 131I-MIBG accompanied by ASCT for high-risk and relapsed neuroblastoma: a pilot study.Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.
P2860
Q33409568-4BA0C101-810E-4F1A-AD39-B78622D2D9FBQ33419875-7E6BAC85-AFAC-4CB8-8B0E-1E3AB5DEAD38Q33420546-37AF7726-BE7A-4D77-8F39-BE7753806057Q33427090-D616A694-FD60-4943-A5ED-129C2EA13CF4Q34424834-C34D8E08-2B2B-47F0-96B7-F013DA918FA5Q34543646-C4819B38-335C-47BD-8013-7534CD32E2CEQ35074813-88F26935-B429-4B6F-81C5-E4A393F40469Q35880923-5DD6BE9D-B5B1-42E8-83CD-C285E0246572Q36678476-646793B6-3DFD-4A76-A8F5-269A698F6471Q37078231-89FC0042-3313-4C57-8BA1-C21CC98D9533Q37334748-83B1C05D-4DEB-4520-911B-693B931325B0Q37716119-50C1894A-7F89-41B1-99C3-5F3CE5358045Q38020428-18F5A51F-EA2B-45C1-882E-47382CD32F98Q38219225-96AA9D4A-72E8-455C-BDC3-DF43C57F3506Q40327489-AE54E171-B2C8-466A-AA1B-CB3DA4EEB9BFQ40777229-E04879CB-0707-448F-B502-157E15FE3045Q41733479-E9E9EBDE-25CC-4788-A916-48EAE9520169Q46344528-87B7F1AD-D795-4C24-B8D4-5D23831AB4C5Q47867820-6D0B328B-878B-442A-B74F-247F161ADC5EQ51125396-80F7842E-677A-40EE-9072-F3C213DECF0FQ51736261-4F34736B-E358-4675-BCCC-7A93B081B0FEQ55618874-1BB3F647-051D-4A52-9D9A-04BCD3559316
P2860
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Hematologic toxicity of high-d ...... py for advanced neuroblastoma.
@ast
Hematologic toxicity of high-d ...... py for advanced neuroblastoma.
@en
type
label
Hematologic toxicity of high-d ...... py for advanced neuroblastoma.
@ast
Hematologic toxicity of high-d ...... py for advanced neuroblastoma.
@en
altLabel
Hematologic toxicity of high-d ...... apy for advanced neuroblastoma
@en
prefLabel
Hematologic toxicity of high-d ...... py for advanced neuroblastoma.
@ast
Hematologic toxicity of high-d ...... py for advanced neuroblastoma.
@en
P2093
P356
P1476
Hematologic toxicity of high-d ...... py for advanced neuroblastoma.
@en
P2093
David V Glidden
Janet Veatch
John Huberty
John M Maris
Julia Messina
Katherine K Matthay
Martin Charron
Randall Hawkins
Steven G DuBois
P304
P356
10.1200/JCO.2004.08.058
P407
P577
2004-06-01T00:00:00Z